Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Operating Expenses (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Operating Expenses over the past 16 years, most recently at $11.1 million for Q2 2025.

  • Quarterly results put Operating Expenses at $11.1 million for Q2 2025, down 26.71% from a year ago — trailing twelve months through May 2025 was $53.1 million (up 4.79% YoY), and the annual figure for FY2025 was $50.6 million, changed 0.27%.
  • Operating Expenses for Q2 2025 was $11.1 million at Lifecore Biomedical, Inc. \De\, down from $12.0 million in the prior quarter.
  • Over the last five years, Operating Expenses for LFCR hit a ceiling of $21.3 million in Q1 2022 and a floor of $7.8 million in Q4 2021.
  • Median Operating Expenses over the past 5 years was $11.5 million (2021), compared with a mean of $12.5 million.
  • Peak annual rise in Operating Expenses hit 204.94% in 2021, while the deepest fall reached 69.03% in 2021.
  • Lifecore Biomedical, Inc. \De\'s Operating Expenses stood at $7.8 million in 2021, then skyrocketed by 42.01% to $11.0 million in 2022, then rose by 3.71% to $11.4 million in 2023, then grew by 14.01% to $13.0 million in 2024, then dropped by 15.03% to $11.1 million in 2025.
  • The last three reported values for Operating Expenses were $11.1 million (Q2 2025), $12.0 million (Q1 2025), and $13.0 million (Q4 2024) per Business Quant data.